Published in Am J Psychiatry on March 01, 2005
Risk Perception in Drug-Dependent Adults With and Without Schizophrenia | NCT01031563
Decision-making impairments in the context of intact reward sensitivity in schizophrenia. Biol Psychiatry (2008) 1.55
Emerging empirical evidence on the ethics of schizophrenia research. Schizophr Bull (2005) 1.16
Two concepts of therapeutic optimism. J Med Ethics (2011) 1.02
Hidden Empirical Research Ethics: A Review of Three Health Journals from 2005 through 2006. J Empir Res Hum Res Ethics (2008) 0.86
Meta-consent in research on decisional capacity: a "Catch-22"? Schizophr Bull (2005) 0.84
Smoked cannabis' psychomotor and neurocognitive effects in occasional and frequent smokers. J Anal Toxicol (2015) 0.80
Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications. Int J Bipolar Disord (2016) 0.78
Traditional ethics and new sensitivities. Schizophr Bull (2005) 0.78
Risk-taking in schizophrenia and controls with and without cannabis dependence. Schizophr Res (2014) 0.76
Ethics in Psychiatric Research: A Review of 25 Years of NIH-funded Empirical Research Projects. AJOB Prim Res (2011) 0.76
Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. J Clin Psychopharmacol (2016) 0.76
Schizophrenia Spectrum Disorders Show Reduced Specificity and Less Positive Events in Mental Time Travel. Front Psychol (2016) 0.75
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry (2005) 6.27
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull (2006) 5.59
Identification of separable cognitive factors in schizophrenia. Schizophr Res (2004) 5.34
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry (2007) 4.44
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res (2004) 3.57
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry (2008) 3.29
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry (2007) 2.98
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
Patients with schizophrenia demonstrate dissociation between affective experience and motivated behavior. J Abnorm Psychol (2007) 2.08
A new perspective on anhedonia in schizophrenia. Am J Psychiatry (2012) 2.08
Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry (2011) 2.02
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Probabilistic reversal learning impairments in schizophrenia: further evidence of orbitofrontal dysfunction. Schizophr Res (2007) 1.98
Delay discounting in schizophrenia. Cogn Neuropsychiatry (2007) 1.94
Anticipatory vs. consummatory pleasure: what is the nature of hedonic deficits in schizophrenia? Psychiatry Res (2011) 1.91
General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biol Psychiatry (2008) 1.86
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry (2013) 1.85
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res (2005) 1.73
Failure of schizophrenia patients to overcome salient distractors during working memory encoding. Biol Psychiatry (2010) 1.73
The construct of attention in schizophrenia. Biol Psychiatry (2008) 1.68
General and specific cognitive deficits in schizophrenia. Biol Psychiatry (2004) 1.64
Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers. Neuropsychopharmacology (2008) 1.64
Maintaining informed consent validity during lengthy research protocols. IRB (2008) 1.62
Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry (2002) 1.62
Deficits in positive reinforcement learning and uncertainty-driven exploration are associated with distinct aspects of negative symptoms in schizophrenia. Biol Psychiatry (2010) 1.58
Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry (2005) 1.57
Decision-making impairments in the context of intact reward sensitivity in schizophrenia. Biol Psychiatry (2008) 1.55
Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology (2006) 1.53
A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull (2013) 1.52
A comparison of cognitive structure in schizophrenia patients and healthy controls using confirmatory factor analysis. Schizophr Res (2006) 1.49
Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology (2009) 1.47
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res (2010) 1.43
Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry (2007) 1.39
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37
A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Am J Psychiatry (2009) 1.36
Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull (2006) 1.35
Schizophrenia in translation: the presence of absence: habenular regulation of dopamine neurons and the encoding of negative outcomes. Schizophr Bull (2006) 1.33
Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr Res (2004) 1.33
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res (2008) 1.30
Optimization of a goal maintenance task for use in clinical applications. Schizophr Bull (2012) 1.30
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull (2006) 1.30
Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr Bull (2006) 1.30
No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology (2005) 1.29
Patients with schizophrenia demonstrate inconsistent preference judgments for affective and nonaffective stimuli. Schizophr Bull (2010) 1.29
Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull (2009) 1.27
The speed of visual attention in schizophrenia: electrophysiological and behavioral evidence. Schizophr Res (2006) 1.26
Optimization and validation of a visual integration test for schizophrenia research. Schizophr Bull (2011) 1.26
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull (2003) 1.24
At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull (2012) 1.24
Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology (2010) 1.23
Factor structure of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.23
Impaired response selection in schizophrenia: evidence from the P3 wave and the lateralized readiness potential. Psychophysiology (2009) 1.23
Social/communication skills, cognition, and vocational functioning in schizophrenia. Schizophr Bull (2006) 1.21
Cognitive factor structure and invariance in people with schizophrenia, their unaffected siblings, and controls. Schizophr Bull (2010) 1.21
Altered probabilistic learning and response biases in schizophrenia: behavioral evidence and neurocomputational modeling. Neuropsychology (2011) 1.21
Relational and Item-Specific Encoding (RISE): task development and psychometric characteristics. Schizophr Bull (2011) 1.21
Impaired control of visual attention in schizophrenia. J Abnorm Psychol (2006) 1.19
The MATRICS Consensus Cognitive Battery (MCCB): clinical and cognitive correlates. Schizophr Res (2011) 1.18
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res (2013) 1.16
The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. Schizophr Res (2010) 1.15
The relationship between working memory capacity and broad measures of cognitive ability in healthy adults and people with schizophrenia. Neuropsychology (2013) 1.11
Emotion regulation abnormalities in schizophrenia: cognitive change strategies fail to decrease the neural response to unpleasant stimuli. Schizophr Bull (2013) 1.11
Another view of therapy for cognition in schizophrenia. Biol Psychiatry (2002) 1.11
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol (2003) 1.10
Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry (2004) 1.09
Less unique variance than meets the eye: overlap among traditional neuropsychological dimensions in schizophrenia. Schizophr Bull (2007) 1.09
Learning-related changes in brain activity following errors and performance feedback in schizophrenia. Schizophr Res (2007) 1.08
The Wisconsin Card Sorting impairment in schizophrenia is evident in the first four trials. Schizophr Res (2007) 1.07
Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia. Psychol Assess (2011) 1.05
The roles of reward, default, and executive control networks in set-shifting impairments in schizophrenia. PLoS One (2013) 1.04
The translation of cognitive paradigms for patient research. Schizophr Bull (2008) 1.03
A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol Psychiatry (2013) 1.03
Visuospatial attention in schizophrenia: deficits in broad monitoring. J Abnorm Psychol (2011) 1.02
Verbal and visual memory: characterizing the clinical and intermediate phenotype in schizophrenia. Schizophr Res (2008) 1.02
White matter alterations in deficit schizophrenia. Neuropsychopharmacology (2008) 1.02
Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res (2012) 1.01
DSM-5 status of psychotic disorders: 1 year prepublication. Schizophr Bull (2012) 1.01
Dissociation of response and feedback negativity in schizophrenia: electrophysiological and computational evidence for a deficit in the representation of value. Front Hum Neurosci (2011) 1.01
Control of working memory content in schizophrenia. Schizophr Res (2011) 1.01
Set-shifting ability and schizophrenia: a marker of clinical illness or an intermediate phenotype? Biol Psychiatry (2008) 1.00
Toward the neural mechanisms of reduced working memory capacity in schizophrenia. Cereb Cortex (2012) 1.00
Imagining the future: degraded representations of future rewards and events in schizophrenia. J Abnorm Psychol (2011) 0.99
Working memory consolidation is abnormally slow in schizophrenia. J Abnorm Psychol (2005) 0.98
The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry (2004) 0.98
Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophr Bull (2006) 0.97